PDF herunterladen
Semin Liver Dis 2009; 29(4): 400-411
DOI: 10.1055/s-0029-1240009
© Thieme Medical Publishers

Genetic Association Studies in Drug-Induced Liver Injury

Ann K. Daly1 , Chris P. Day1
  • 1Institute of Cellular Medicine, Newcastle University Medical School, Newcastle upon Tyne, United Kingdom
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
13. Oktober 2009 (online)

    Lizenzen und Reprints

ABSTRACT

Genetic studies on drug-induced liver injury (DILI) have proved challenging, both because of their rarity and their difficulty in replicating observed effects. However, significant progress has now been achieved by both candidate-gene and genome-wide association studies. These two approaches are considered in detail, together with examples of DILI due to specific drugs where consistent associations have been reported. Particular consideration is given to associations between antituberculosis drug-related liver injury and the “slow acetylator” genotype for N-acetyltransferase 2, amoxicillin/clavulanate-related liver injury, and the human leukocyte antigen (HLA) class II DRB1*1501 allele and flucloxacillin-related injury and the HLA class I B*5701 allele. Although these associations are drug-specific, the possibility that additional, more general susceptibility genes for DILI exist requires further investigation, ideally by genome-wide association studies involving international collaboration. The possibility of interethnic variation in susceptibility to DILI also requires further study.

KEYWORDS

Human leukocyte antigen - genome-wide association - candidate-gene - N-acetyltransferase 2 - single nucleotide polymorphism

REFERENCES

  • 1 Kaplowitz N. Idiosyncratic drug hepatotoxicity.  Nat Rev Drug Discov. 2005;  4(6) 489-499
    CrossrefPubMedGoogle Scholar
  • 2 Manolio T A, Brooks L D, Collins F SA. A HapMap harvest of insights into the genetics of common disease.  J Clin Invest. 2008;  118(5) 1590-1605
    Google Scholar
  • 3 Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.  Am J Respir Crit Care Med. 2003;  167(11) 1472-1477
    CrossrefPubMedGoogle Scholar
  • 4 Sarma G R, Immanuel C, Kailasam S, Narayana A S, Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin.  Am Rev Respir Dis. 1986;  133(6) 1072-1075
    PubMedGoogle Scholar
  • 5 Daly A K. Pharmacogenetics of the major polymorphic metabolizing enzymes.  Fundam Clin Pharmacol. 2003;  17(1) 27-41
    CrossrefPubMedGoogle Scholar
  • 6 Eichelbaum M, Musch E, Castro-Parra M, Vonsassen W. Isoniazid hepatotoxicity in relation to acetylator phenotype and isoniazid metabolism.  Br J Clin Pharmacol. 1982;  14(4) P575-P576
    PubMedGoogle Scholar
  • 7 Sarich T C, Adams S P, Petricca G, Wright J M. Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor.  J Pharmacol Exp Ther. 1999;  289(2) 695-702
    PubMedGoogle Scholar
  • 8 Ohno M, Yamaguchi I, Yamamoto I et al.. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.  Int J Tuberc Lung Dis. 2000;  4(3) 256-261
    PubMedGoogle Scholar
  • 9 Huang Y S, Chern H D, Su W J et al.. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.  Hepatology. 2002;  35(4) 883-889
    CrossrefPubMedGoogle Scholar
  • 10 Cho H J, Koh W J, Ryu Y J et al.. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.  Tuberculosis (Edinb). 2007;  87(6) 551-556
    CrossrefPubMedGoogle Scholar
  • 11 Vuilleumier N, Rossier M F, Chiappe A et al.. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.  Eur J Clin Pharmacol. 2006;  62(6) 423-429
    CrossrefPubMedGoogle Scholar
  • 12 Possuelo L G, Castelan J A, de Brito T C et al.. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil.  Eur J Clin Pharmacol. 2008;  64(7) 673-681
    CrossrefPubMedGoogle Scholar
  • 13 Bozok Cetintaş V, Erer O F, Kosova B et al.. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests.  Tuberk Toraks. 2008;  56(1) 81-86
    PubMedGoogle Scholar
  • 14 Daly A K. Pharmacogenetics of the cytochromes P450.  Curr Top Med Chem. 2004;  4(16) 1733-1744
    CrossrefPubMedGoogle Scholar
  • 15 Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene.  J Biochem. 1991;  110(4) 559-565
    PubMedGoogle Scholar
  • 16 Kato S, Shields P G, Caporaso N E et al.. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk.  Cancer Res. 1992;  52(23) 6712-6715
    PubMedGoogle Scholar
  • 17 Huang Y S, Chern H D, Su W J et al.. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.  Hepatology. 2003;  37(4) 924-930
    CrossrefPubMedGoogle Scholar
  • 18 Roy B, Chowdhury A, Kundu S et al.. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ‘null’ mutation.  J Gastroenterol Hepatol. 2001;  16(9) 1033-1037
    CrossrefPubMedGoogle Scholar
  • 19 Huang Y S, Su W J, Huang Y H et al.. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury.  J Hepatol. 2007;  47(1) 128-134
    CrossrefPubMedGoogle Scholar
  • 20 Leiro V, Fernández-Villar A, Valverde D et al.. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population.  Liver Int. 2008;  28(6) 835-839
    CrossrefPubMedGoogle Scholar
  • 21 Sharma S K, Balamurugan A, Saha P K, Pandey R M, Mehra N K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.  Am J Respir Crit Care Med. 2002;  166(7) 916-919
    CrossrefPubMedGoogle Scholar
  • 22 Kindmark A, Jawaid A, Harbron C G et al.. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis.  Pharmacogenomics J. 2008;  8(3) 186-195
    CrossrefPubMedGoogle Scholar
  • 23 Andrade R J, Lucena M I, Fernández M C Spanish Group for the Study of Drug-Induced Liver Disease et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.  Gastroenterology. 2005;  129(2) 512-521
    CrossrefPubMedGoogle Scholar
  • 24 Jinjuvadia K, Kwan W, Fontana R J. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury.  Am J Gastroenterol. 2007;  102(11) 2437-2443
    CrossrefPubMedGoogle Scholar
  • 25 Stricker B H, Blok A P, Claas F H, Van Parys G E, Desmet V J. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases.  Hepatology. 1988;  8(3) 599-606
    CrossrefPubMedGoogle Scholar
  • 26 Berson A, Fréneaux E, Larrey D et al.. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis.  J Hepatol. 1994;  20(3) 336-342
    CrossrefPubMedGoogle Scholar
  • 27 Hautekeete M L, Horsmans Y, Van Waeyenberge C et al.. HLA association of amoxicillin-clavulanate–induced hepatitis.  Gastroenterology. 1999;  117(5) 1181-1186
    CrossrefPubMedGoogle Scholar
  • 28 O'Donohue J, Oien K A, Donaldson P et al.. Co-amoxiclav jaundice: clinical and histological features and HLA class II association.  Gut. 2000;  47(5) 717-720
    CrossrefPubMedGoogle Scholar
  • 29 Donaldson P T, Bhatnagar P, Graham J et al.. Susceptibility to drug induced liver injury determined by HLA class II genotype. 59th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA; October 31–November 4, 2008
    PubMedGoogle Scholar
  • 30 Andrade R J, Lucena M I, Alonso A et al.. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease.  Hepatology. 2004;  39(6) 1603-1612
    CrossrefPubMedGoogle Scholar
  • 31 Lucena M I, Andrade R J, Martínez C Spanish Group for the Study of Drug-Induced Liver Disease et al. Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury.  Hepatology. 2008;  48(2) 588-596
    CrossrefPubMedGoogle Scholar
  • 32 Russmann S, Kaye J A, Jick S S, Jick H. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.  Br J Clin Pharmacol. 2005;  60(1) 76-82
    CrossrefPubMedGoogle Scholar
  • 33 Daly A K, Donaldson P T, Bhatnagar P et al.. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.  Nat Genet. 2009;  41(7) 816-819
    CrossrefPubMedGoogle Scholar
  • 34 Mallal S, Phillips E, Carosi G PREDICT-1 Study Team et al. HLA-B*5701 screening for hypersensitivity to abacavir.  N Engl J Med. 2008;  358(6) 568-579
    CrossrefPubMedGoogle Scholar
  • 35 Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden.  Scand J Gastroenterol. 2005;  40(9) 1095-1101
    CrossrefPubMedGoogle Scholar
  • 36 Boelsterli U A. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity.  Toxicol Appl Pharmacol. 2003;  192(3) 307-322
    CrossrefPubMedGoogle Scholar
  • 37 Boelsterli U A, Zimmerman H J, Kretz-Rommel A. Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology.  Crit Rev Toxicol. 1995;  25(3) 207-235
    CrossrefPubMedGoogle Scholar
  • 38 Aithal G P, Daly A K, Leathart J, Yuanneng C P, Day C P. Promoter polymorphisms of interleukin-10 (IL-10) and interleukin-4 (IL-4) predict the risk of diclofenac-induced hepatotoxicity.  Gastroenterology. 2000;  118(4) 1077
    PubMedGoogle Scholar
  • 39 Daly A K, Aithal G P, Leathart J B, Swainsbury R A, Dang T S, Day C P. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.  Gastroenterology. 2007;  132(1) 272-281
    CrossrefPubMedGoogle Scholar
  • 40 Haenisch S, Zimmermann U, Dazert E et al.. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex.  Pharmacogenomics J. 2007;  7(1) 56-65
    CrossrefPubMedGoogle Scholar
  • 41 Choi J H, Ahn B M, Yi J et al.. MRP2 haplotypes confer differential susceptibility to toxic liver injury.  Pharmacogenet Genomics. 2007;  17(6) 403-415
    CrossrefPubMedGoogle Scholar
  • 42 Deng X, Stachlewitz R F, Liguori M J et al.. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation.  J Pharmacol Exp Ther. 2006;  319(3) 1191-1199
    CrossrefPubMedGoogle Scholar
  • 43 Bourdi M, Masubuchi Y, Reilly T P et al.. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase.  Hepatology. 2002;  35(2) 289-298
    CrossrefPubMedGoogle Scholar
  • 44 Bourdi M, Eiras D P, Holt M P et al.. Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury.  Chem Res Toxicol. 2007;  20(2) 208-216
    CrossrefPubMedGoogle Scholar
  • 45 Yee S B, Bourdi M, Masson M J, Pohl L R. Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease.  Chem Res Toxicol. 2007;  20(5) 734-744
    CrossrefPubMedGoogle Scholar
  • 46 Grove J, Daly A K, Bassendine M F, Day C P. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis.  Hepatology. 1997;  26(1) 143-146
    CrossrefPubMedGoogle Scholar
  • 47 Grove J, Daly A K, Bassendine M F, Gilvarry E, Day C P. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease.  Gut. 2000;  46(4) 540-545
    CrossrefPubMedGoogle Scholar
  • 48 Aithal G P, Ramsay L, Daly A K et al.. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity.  Hepatology. 2004;  39(5) 1430-1440
    CrossrefPubMedGoogle Scholar
  • 49 Pachkoria K, Lucena M I, Crespo E Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos (GEHAM)) et al. Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome.  J Hepatol. 2008;  49(1) 107-114
    CrossrefPubMedGoogle Scholar
  • 50 Lang C, Meier Y, Stieger B et al.. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury.  Pharmacogenet Genomics. 2007;  17(1) 47-60
    CrossrefPubMedGoogle Scholar
  • 51 Bhatnagar P, Day C P, Aithal G et al.. Genetic variants of hepatic transporters and susceptibility to drug induced liver injury.  Toxicology. 2008;  253(1–3) 10
    CrossrefPubMedGoogle Scholar
  • 52 Hirschhorn J N. Genomewide association studies—illuminating biologic pathways.  N Engl J Med. 2009;  360(17) 1699-1701
    CrossrefPubMedGoogle Scholar
  • 53 International HapMap Consortium . A haplotype map of the human genome.  Nature. 2005;  437(7063) 1299-1320
    CrossrefPubMedGoogle Scholar
  • 54 Hardy J, Singleton A. Genomewide association studies and human disease.  N Engl J Med. 2009;  360(17) 1759-1768
    CrossrefPubMedGoogle Scholar
  • 55 Wellcome Trust Case Control Consortium . Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.  Nature. 2007;  447(7145) 661-678
    CrossrefPubMedGoogle Scholar
  • 56 Hirschfield G M, Liu X, Xu C et al.. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants.  N Engl J Med. 2009;  360(24) 2544-2555
    CrossrefPubMedGoogle Scholar
  • 57 Spencer C CA, Su Z, Donnelly P, Marchini J. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip.  PLoS Genet. 2009;  5(5) e1000477
    CrossrefPubMedGoogle Scholar
  • 58 Nelson M R, Bacanu S A, Mosteller M et al.. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.  Pharmacogenomics J. 2009;  9(1) 23-33
    CrossrefPubMedGoogle Scholar
  • 59 de Bakker P I, Ferreira M A, Jia X, Neale B M, Raychaudhuri S, Voight B F. Practical aspects of imputation-driven meta-analysis of genome-wide association studies.  Hum Mol Genet. 2008;  17(R2) R122-R128
    CrossrefPubMedGoogle Scholar
  • 60 Novembre J, Johnson T, Bryc K et al.. Genes mirror geography within Europe.  Nature. 2008;  456(7218) 98-101
    CrossrefPubMedGoogle Scholar
  • 61 Campbell C D, Ogburn E L, Lunetta K L et al.. Demonstrating stratification in a European American population.  Nat Genet. 2005;  37(8) 868-872
    CrossrefPubMedGoogle Scholar
  • 62 Price A L, Patterson N J, Plenge R M, Weinblatt M E, Shadick N A, Reich D. Principal components analysis corrects for stratification in genome-wide association studies.  Nat Genet. 2006;  38(8) 904-909
    CrossrefPubMedGoogle Scholar
  • 63 Tian C, Gregersen P K, Seldin M F. Accounting for ancestry: population substructure and genome-wide association studies.  Hum Mol Genet. 2008;  17(R2) R143-R150
    CrossrefPubMedGoogle Scholar
  • 64 Devlin B, Roeder K. Genomic control for association studies.  Biometrics. 1999;  55(4) 997-1004
    CrossrefPubMedGoogle Scholar
  • 65 Link E, Parish S, Armitage J SEARCH Collaborative Group et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study.  N Engl J Med. 2008;  359(8) 789-799
    CrossrefPubMedGoogle Scholar
  • 66 Hoofnagle J H. Drug-induced liver injury network (DILIN).  Hepatology. 2004;  40(4) 773
    PubMedGoogle Scholar
  • 67 Molokhia M, McKeigue P. EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions.  Pharmacogenomics. 2006;  7(4) 633-638
    CrossrefPubMedGoogle Scholar
  • 68 Goldstein D B. Common genetic variation and human traits.  N Engl J Med. 2009;  360(17) 1696-1698
    CrossrefPubMedGoogle Scholar
  • 69 Ghodke Y, Joshi K, Chopra A, Patwardhan B. HLA and disease.  Eur J Epidemiol. 2005;  20(6) 475-488
    CrossrefPubMedGoogle Scholar
  • 70 Pachkoria K, Lucena M I, Ruiz-Cabello F, Crespo E, Cabello M R, Andrade R J. Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos) . Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).  Br J Pharmacol. 2007;  150(6) 808-815
    CrossrefPubMedGoogle Scholar
  • 71 Green V J, Pirmohamed M, Kitteringham N R, Knapp M J, Park B K. Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis.  Br J Clin Pharmacol. 1995;  39(4) 411-415
    CrossrefPubMedGoogle Scholar
  • 72 Dupont I, Bodénez P, Berthou F, Simon B, Bardou L G, Lucas D. Cytochrome P-450 2E1 activity and oxidative stress in alcoholic patients.  Alcohol Alcohol. 2000;  35(1) 98-103
    PubMedGoogle Scholar
  • 73 Watanabe I, Tomita A, Shimizu M et al.. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus.  Clin Pharmacol Ther. 2003;  73(5) 435-455
    CrossrefPubMedGoogle Scholar
  • 74 Ueda K, Ishitsu T, Seo T et al.. Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity.  Pharmacogenomics. 2007;  8(5) 435-442
    CrossrefPubMedGoogle Scholar
  • 75 De Sousa M, Pirmohamed M, Kitteringham N R, Woolf T, Park B K. No association between tacrine transaminitis and the glutathione transferase theta genotype in patients with Alzheimer's disease.  Pharmacogenetics. 1998;  8(4) 353-355
    PubMedGoogle Scholar
  • 76 Acuña G, Foernzler D, Leong D et al.. Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity.  Pharmacogenomics J. 2002;  2(5) 327-334
    CrossrefPubMedGoogle Scholar
  • 77 Carr D F, Alfirevic A, Tugwood J D et al.. Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity.  Pharmacogenet Genomics. 2007;  17(11) 961-972
    CrossrefPubMedGoogle Scholar

Professor Chris P DayM.D. Ph.D. F.Med.Sci. 

Institute of Cellular Medicine, Newcastle University Medical School, Framlington Place

Newcastle upon Tyne NE2 4HH, UK

eMail: C.P.Day@ncl.ac.uk

      >